Peptic Ulcer Hemorrhage Study

To evaluate the efficacy and safety of intravenous pantoprazole in the prevention of rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.

Official Title

An efficacy and safety study of intravenous pantoprazole in the prevention of recurrent peptic ulcer bleeding after successful hemostasis.

Conditions

– Peptic Ulcer

Study Type

Interventional

Study Design

Prevention

Further Details

Study Start

Eligibility & Criteria

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria Inclusion Criteria:Patients must be men or non-pregnant women at least 18 years of age. Patients who present with a gastric or duodenal ulcer with endoscopic appearance of spurting, oozing, or nonbleeding visible vessel (NBVV). Patients must be at high risk for rebleeding. Successful endoscopic hemostasis must be established. Patients must be capable of understanding and giving signed and dated informed consent. Exclusion Criteria:Patients with ulcer appearance of clean base or flat pigmented spot; adherent clots not removed by irrigation. Patients presenting with active bleeding and/or NBVV at 2 or more separate sites. Patients with any severe concomitant diseases or severe injuries. Patients with gastrointestinal bleeding other than peptic ulcer. Patients who have undergone gastric acid reducing surgery (eg, vagotomy or antrectomy).

Total Enrolment

Contact Details

[1] Wyeth-Ayerst Research